ProfileGDS4814 / ILMN_1748596
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 9% 12% 29% 35% 3% 29% 6% 22% 15% 31% 13% 27% 26% 20% 13% 16% 42% 21% 31% 9% 22% 12% 1% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)40.78069
GSM780708Untreated after 4 days (C2_1)41.646612
GSM780709Untreated after 4 days (C3_1)45.399929
GSM780719Untreated after 4 days (C1_2)46.707735
GSM780720Untreated after 4 days (C2_2)38.09993
GSM780721Untreated after 4 days (C3_2)45.338829
GSM780710Trastuzumab treated after 4 days (T1_1)39.73856
GSM780711Trastuzumab treated after 4 days (T2_1)43.890122
GSM780712Trastuzumab treated after 4 days (T3_1)42.465315
GSM780722Trastuzumab treated after 4 days (T1_2)45.719431
GSM780723Trastuzumab treated after 4 days (T2_2)41.852613
GSM780724Trastuzumab treated after 4 days (T3_2)44.900927
GSM780713Pertuzumab treated after 4 days (P1_1)44.704826
GSM780714Pertuzumab treated after 4 days (P2_1)43.606220
GSM780715Pertuzumab treated after 4 days (P3_1)42.093213
GSM780725Pertuzumab treated after 4 days (P1_2)42.605516
GSM780726Pertuzumab treated after 4 days (P2_2)48.162742
GSM780727Pertuzumab treated after 4 days (P3_2)43.814721
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)45.716931
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)40.77379
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)43.874322
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)41.704512
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)35.71091